Latest revenue
$0
as of 2026-03-31
Latest net income
$-7.0M
as of 2026-03-31
Net margin
—
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ADGM is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $16.1M
- Enterprise value
- $77.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.81×
- Dividend yield
- 0.0%
- 52-wk high
- $2.58
- 52-wk low
- $0.70
- Beta
- —
- Shares out
- 22.2M
5-year trend
What this company does
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q (this “Report”). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these…
AI summary unavailable — showing raw filing excerpt
Generated from ADGM's filing dated 2026-05-12
Key risks
Item 1A. Risk Factors. Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that we currently consider immaterial. If any of such risks and uncertainties actually occurs, our business, prospects, financial condition, cash flows, or operating results could differ materially from the plans, projections, and other forward-looking statements included in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Annual Report on Form 10-K and in our other public filings. For more information, see the section titled “Special…
AI summary unavailable — showing raw filing excerpt
Generated from ADGM's filing dated 2026-05-12
Profitability
Operating margin
-9314.0%
Net margin
-12196.7%
Return on equity
-126.0%
430.1%Return on assets
-58.0%
89.2%Leverage
Debt / equity
1.17×
18.2%Long-term debt / equity
1.06×
30.9%Debt / assets
54.0%
8.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $0 | — | $-7.0M | +9.3% | — |
Q4 2025 2025-12-31 | — | — | $-3.3M | — | — |
Q3 2025 2025-09-30 | $0 | — | $-10.1M | — | — |
Q2 2025 2025-06-30 | — | — | $-3.9M | -453.0% | — |
Q1 2025 2025-03-31 | $0 | -100.0% | $-7.7M | -443.0% | — |
Q3 2024 2024-07-30 | $333.0K | — | $-21.3M | — | -6389.8% |
Q2 2024 2024-06-30 | $254.0K | — | $-713.8K | — | -281.0% |
Q1 2024 2024-03-31 | $26.0K | — | $-1.4M | — | -5463.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on ADGM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$4.5M
Insider selling
$0
Net activity
+$4.5M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ADGM
Institutional value
$140.1K
Total shares held
121.9K
Distinct holders
6
-15 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD FIDUCIARY TRUST CO | 53.8K | $61.8K | — | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 39.6K | $45.5K | — | New |
| 3 | Granite Investment Partners, LLC | 27.1K | $31.1K | — | New |
| 4 | JPMORGAN CHASE & CO | 975 | $1.1K | — | New |
| 5 | Crewe Advisors LLC | 500 | $575 | +0 (+0.0%) | No change |
| 6 | CITIGROUP INC | 1 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ADGM's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.